

FINANCIAL UPDATE, INCLUDING FORECAST

BOARD MEETING

Barry Greene

28-29 November 2018, Geneva, Switzerland



Decisions for consideration at this Board meeting

Decisions for consideration by the Board	US\$ million	Decision amount	Already in Forecast	Addition to Forecast 2016-2020	Addition to Forecast 2021-2025
(a) Vaccine Investment Strategy - Cholera (Bridge Funding & Learning Agenda) <i>Investment return: Direct Health impact</i>		44	1	43	
(b) Vaccine Investment Strategy - excl Cholera Bridge Funding <i>Investment return: Direct Health impact</i>				VIS	360
(c) Vaccine Investment Strategy - Learning Agenda, excl Cholera <i>Investment return: Direct Health impact</i>		7	3	4	13
(d) Gavi's support for IPV post 2020 <i>Investment return: Global Health Security</i>					850
(e) Pandemic Influenza Preparedness <i>Investment return: Global Health Security</i>		2	1	1	2
(f) India: IPV support (if at upper range of options) <i>Investment return: Global Health Security</i>		40		40	
(g) Gavi Support for Yellow Fever Diagnostic Capacity <i>Investment return: Direct Health impact</i>		8	2	6	5
(h) CEPI -- Fully funded by specific pledge from Kingdom of Norway to IFFIm <i>Investment return: Global Health Security</i>		77		77	
(i) Engagement with Country Post-Transition: Angola and Timor-Leste <i>Investment return: Direct Health impact</i>		2		2	8
(j) Congo Republic exceptional eligibility 2019 (note 4) <i>Investment return: Direct Health impact</i>		4	4		
(k) 2019 UNICEF Procurement Fees - CCEOP		4.3	3.6	0.7	
				174	1,238
				\$0.2 bn	\$1.2 bn

Addition to forecast expenditure

Evolution of expenditure, before new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year	
2016-2020	9,205 \$9.2 bn	353	\$200m IPV 2019-2020, \$61m Nigeria, \$52m Cholera, etc.
2021-2025 tentative	8,299 \$8.3 bn	422	\$396 Nigeria, \$26m Pneumo catch-up

Evolution of expenditure, before new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	
2016-2020	9,205 \$9.2 bn	353	(524)	9,034 \$9.0 bn	Supply constraints – Rota, HPV Price assumptions
2021-2025 tentative	8,299 \$8.3 bn	422	(1,367)	7,354 \$7.4 bn	Critical review of assumptions, including for country readiness <ul style="list-style-type: none"> • Typhoid • Measles-Rubella • Cash-based support • PEF programmatic

Evolution of expenditure, including new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	Impact of Nov 2018 decisions	New Forecast Nov 2018 Board									
2016-2020	9,205 \$9.2 bn	353	(524)	9,034 \$9.0 bn	174	9,207 \$9.2 bn	<table border="1"> <tr><td>VIS</td><td>47</td></tr> <tr><td>CEPI</td><td>77</td></tr> <tr><td>India IPV</td><td>40</td></tr> <tr><td>Other</td><td>10</td></tr> </table>	VIS	47	CEPI	77	India IPV	40	Other	10
VIS	47														
CEPI	77														
India IPV	40														
Other	10														
2021-2025 tentative	8,299 \$8.3 bn	422	(1,367)	7,354 \$7.4 bn	1,238	8,593 \$8.6 bn	<table border="1"> <tr><td>VIS</td><td>373</td></tr> <tr><td>IPV post-2020</td><td>850</td></tr> <tr><td>Other</td><td>15</td></tr> </table>	VIS	373	IPV post-2020	850	Other	15		
VIS	373														
IPV post-2020	850														
Other	15														

Evolution of expenditure, including new decisions

Expenditure estimate US\$ million cash-flow basis	Last Forecast Nov 2017 Board	Decisions already made this year	Change upon updating estimates	Sub-total prior to Nov 2018 decisions	Impact of Nov 2018 decisions	New Forecast Nov 2018 Board	
2016-2020	9,205 \$9.2 bn	353	(524)	9,034 \$9.0 bn	174	9,207 \$9.2 bn	Overall, unchanged
2021-2025 tentative	8,299 \$8.3 bn	422	(1,367)	7,354 \$7.4 bn	1,238	8,593 \$8.6 bn	Overall, plus \$0.3bn
							Plus potential provision for strategic initiatives and Malaria \$500m

Resourcing of needs, including the new decisions

Expenditure estimate
US\$ million, cash-flow basis

Expenditure
projection
Nov 2018
Board

Assured
resources

Formulaic
Allowance
for additional
contributions

2016-2020

\$9.2 bn

\$9.4 bn

\$0.4 bn

2021-2025 tentative

\$8.6 bn

\$1.7 bn

\$7.2 bn

Potential addition of **\$500m** for
Strategic Initiatives and Malaria, for
consideration in **strategy 2021-2025**

\$0.5 bn

\$9.1 bn

\$8.9 bn

This is **NOT** an estimate
of 2021-2025 resources

**Resources do not
include funding for IPV
(was \$300m in 2016-2020)**

Recommendation (1/2)

The Gavi Alliance Audit and Finance Committee reviewed the Financial Forecast and recommends to the Gavi Alliance Board that it:

- a) **Approve** the Financial Forecast for the period 2016-2020 as set out in Section B of Doc 05.
- b) **Take note of** the indicative Financial Projections for the 2021-2025 period, as set out in Section B of Doc 05, which is based on existing and anticipated programmatic commitments but is dependent on Board approval of the next Gavi Strategy, and any potential programmatic and policy shifts for the given period.

Recommendation (2/2)

- c) **Authorise** the Gavi Secretariat to allot funding in 2019 for new programmes and for the continuation and adjustment of funding to existing programmes, in accordance with the Programme Funding Policy. In making such allotment decisions, the Secretariat will take into consideration the development of the strategy for the 2021-2025 period.
- d) **Approve** within the overall Partners Engagement Framework: an amount of US\$ 0.7 million in 2019 for UNICEF Supply Division for fees to implement cold chain equipment, in addition to the US\$ 3.6 million already approved for 2019 by the Board in November 2017

Thank you



www.gavi.org